Metraipolis › archive › dc_730cfc8d46ee

GLP-1 receptor agonists, metabolic syndrome, and Alzheimer's disease: Lessons and opportunities from the EVOKE trials — Europe PMC PMID:42580680

Source: Europe PMC (en)
Original: https://europepmc.org/article/MED/42580680
DOI: 10.1111/jne.70246
License (as archived): solo-consultazione
Archived: 2026-10-08T05:55:36.199Z
SHA-256 of the archived text: b803b6c961f87f04d1e65a275e672a5ab631d6761d50e32ff181c91e8e2b6cd0
Stable URL of this page: https://metraipolis.com/documento/dc_730cfc8d46ee

How to cite

GLP-1 receptor agonists, metabolic syndrome, and Alzheimer's disease: Lessons and opportunities from the EVOKE trials — Europe PMC PMID:42580680 — Europe PMC (en), https://europepmc.org/article/MED/42580680 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_730cfc8d46ee (Metraipolis archive dc_730cfc8d46ee, sha256 b803b6c961f87f04d1e65a275e672a5ab631d6761d50e32ff181c91e8e2b6cd0)

BibTeX

@misc{dc730cfc8d46ee,
  title = {GLP-1 receptor agonists, metabolic syndrome, and Alzheimer's disease: Lessons and opportunities from the EVOKE trials — Europe PMC PMID:42580680},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/42580680},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_730cfc8d46ee; sha256 b803b6c961f87f04d1e65a275e672a5ab631d6761d50e32ff181c91e8e2b6cd0},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42580680. Agents can read the archived copy with the MCP tool read_document.